Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cilostazol + prednisolone is a combination of two pharmaceutical agents, each with distinct mechanisms and clinical uses. Cilostazol is an antiplatelet agent and vasodilator, primarily used for the symptomatic relief of intermittent claudication in patients with peripheral arterial disease. It works by inhibiting phosphodiesterase III, leading to increased cyclic AMP in platelets and blood vessels, which inhibits platelet aggregation and promotes vasodilation[1][3][8]. Prednisolone is a synthetic glucocorticoid corticosteroid used for its potent anti-inflammatory and immunosuppressive effects across a wide range of conditions including allergic reactions, autoimmune diseases, asthma, arthritis, inflammatory bowel disease, and more[4][7]. It acts as an agonist at the glucocorticoid receptor to modulate gene expression that suppresses inflammation[4][7]. The combination may be considered when both antiplatelet/vasodilatory effects (from cilostazol) and anti-inflammatory/immunosuppressive actions (from prednisolone) are desired; however, there are no widely recognized fixed-dose combination products or unique brand names for this pairing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cilostazol + prednisolone.